Merson Pharma’s Timolol Maleate Gel, world’s first topical treatment for infant hemangioma, approved in China

On October 11, 2025, Beijing Merson Pharmaceutical Technology Development Co., Ltd. announced that its Class 2 new chemical drug, Timolol Maleate Gel (Chinese brand name: 贝美净), had officially received marketing approval from the China National Medical Products Administration (NMPA) on September 30, 2025.

This product is the first topical gel formulation globally approved for the treatment of proliferative superficial infantile hemangiomas. As a topical therapeutic agent specifically designed for infants and young children, its launch successfully addresses both the market and clinical gap for external treatment options in this disease area, offering a safe, effective, and convenient new therapeutic choice for affected children.

Infantile hemangioma is the most common benign tumor in infancy, with a global estimated incidence ranging between 5% and 12%. Its distribution shows significant ethnic variations, with the superficial type accounting for nearly 70% of cases. Clinical expert consensus recommends early intervention for proliferative superficial infantile hemangiomas.

Beijing Merson Pharmaceutical Technology Development Co., Ltd., founded in 2003 and headquartered in Beijing, is committed to building a fully integrated industrial system that spans the research, production, and commercialization of improved new drugs and complex, high-difficulty formulations. The company is also actively expanding its pipeline in pediatric medicines and specialty drugs.

By establishing deep alliances with GMP-compliant strategic partners, Merson has constructed a comprehensive industry chain covering both R&D and manufacturing. Supported by a rigorous quality management system, the company ensures full compliance and high quality throughout the entire product journey—from the laboratory to the market.